Metabolomic analysis of pressure-overloaded and infarcted mouse hearts

Circulation: Heart Failure

Volumn 7, Issue 4, 2014, Pages 634-642

  Sansbury, Brian E ^a,b   DeMartino, Angelica M ^a   Xie, Zhengzhi ^a,b   Brooks, Alan C ^a,c   Brainard, Robert E ^a   Watson, Lewis J ^a   DeFilippis, Andrew P ^e   Cummins, Timothy D ^b   Harbeson, Matthew A ^b   Brittian, Kenneth R ^a   Prabhu, Sumanth D ^d   Bhatnagar, Aruni ^a,c   Jones, Steven P ^a   Hill, Bradford G ^a,c  

^a University of Louisville School of Medicine   (United States)

^b Diabetes and Obesity Center   (United States)

^c Department of Biochemistry and Molecular Biology ^*  (United States)

^d University of Alabama at Birmingham   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amino acids; Glycolysis; Heart failure; Hypertrophy; Metabolomics; Mitochondria; Oxidative stress

Indexed keywords

2 HYDROXYGLUTARIC ACID; ACYLCARNITINE; ASCORBIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; CREATINE; DEHYDROASCORBIC ACID; FATTY ACID; FLAVINE ADENINE NUCLEOTIDE; GLUTATHIONE DISULFIDE; GLYCEROPHOSPHATE; HEME; LINOLEIC ACID; MALIC ACID; METHIONINE; N(G),N(G) DIMETHYLARGININE; OLEOYLCARNITINE; PALMITOYLCARNITINE; PANTOTHENIC ACID; PHOSPHOETHANOLAMINE; PURINE; PUTRESCINE; PYRUVIC ACID; SPERMIDINE; SPHINGOLIPID; UNCLASSIFIED DRUG; URACIL; AMINO ACID;

ADULT; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORONARY ARTERY OCCLUSION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; IN VIVO STUDY; INSULIN RESISTANCE; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; TANDEM MASS SPECTROMETRY; ANIMAL; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; ECHOCARDIOGRAPHY; ENERGY METABOLISM; GLYCOLYSIS; HEART FAILURE; HEART MUSCLE; HEART STROKE VOLUME; HYPERTROPHY; METABOLISM; MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMINO ACIDS; GLYCOLYSIS; HEART FAILURE; HYPERTROPHY; METABOLOMICS; MITOCHONDRIA; OXIDATIVE STRESS;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENERGY METABOLISM; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; OXIDATIVE STRESS; STROKE VOLUME; TANDEM MASS SPECTROMETRY;

EID: 84907424457     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001151     Document Type: Article

References (50)

1. Olson RE, Schwartz WB. Myocardial metabolism in congestive heart failure. Medicine. 1951;30:21-41.
2. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135-145.
3. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434-448.
4. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-1129.
5. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207-258.
6. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267(2 Pt 2):H742-H750.
7. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol. 1994;26:1371-1375.
8. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, Hoppel CL, Imai M, Rastogi S, Sabbah HN, Stanley WC. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2004;287:H1538-H1543.
9. Remondino A, Rosenblatt-Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA, Jorge-Costa M, Lerch R. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol. 2000;32:2025-2034.
10. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED, Komuro I. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010;120:1506-1514.
11. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, Lopaschuk GD. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 2013; 6:1039-1048.
12. Mervaala E, Biala A, Merasto S, Lempiäinen J, Mattila I, Martonen E, Eriksson O, Louhelainen M, Finckenberg P, Kaheinen P, Muller DN, Luft FC, Lapatto R, Oresic M. Metabolomics in angiotensin II-induced cardiac hypertrophy. Hypertension. 2010;55:508-515.
13. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, Iwanaga Y, Narazaki M, Matsuda T, Soga T, Kita T, Kimura T, Shioi T. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail. 2010;3:420-430.
14. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126:1110-1120.
15. Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, Long BW, Prabhu SD, Xuan YT, Jones SP. O-linked β-Nacetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci U S A. 2010;107:17797-17802.
16. Facundo HT, Brainard RE, Watson LJ, Ngoh GA, Hamid T, Prabhu SD, Jones SP. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2012;302:H2122-H2130.
17. Sansbury BE, Cummins TD, Tang Y, Hellmann J, Holden CR, Harbeson MA, Chen Y, Patel RP, Spite M, Bhatnagar A, Hill BG. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res. 2012;111:1176-1189.
18. Ryals J, Lawton K, Stevens D, Milburn M. Metabolon, Inc. Pharmacogenomics. 2007;8:863-866.
19. Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, Palma MJ, Roberts LD, Dejam A, Souza AL, Deik AA, Magnusson M, Fox CS, O'Donnell CJ, Vasan RS, Melander O, Clish CB, Gerszten RE, Wang TJ. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125:2222-2231.
20. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr. 2011;2:445-456.
21. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311-326.
22. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, Ferrannini E. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98:2094-2099.
23. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res. 2004;61:297-306.
24. Gudbjarnason S, Telerman M, Bing RJ. Protein metabolism in cardiac hypertrophy and heart failure. Am J Physiol. 1964;206:294-298.
25. Nagai R, Low RB, Stirewalt WS, Alpert NR, Litten RZ. Efficiency and capacity of protein synthesis are increased in pressure overload cardiac hypertrophy. Am J Physiol. 1988;255:H325-H328.
26. Koide T, Ozeki K. Increased amino acid transport in experimentally hypertrophied rat heart. Jpn Heart J. 1971;12:177-184.
27. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr. 2007;27:19-40.
28. Pellieux C, Montessuit C, Papageorgiou I, Pedrazzini T, Lerch R. Differential effects of high-fat diet on myocardial lipid metabolism in failing and nonfailing hearts with angiotensin II-mediated cardiac remodeling in mice. Am J Physiol Heart Circ Physiol. 2012;302:H1795-H1805.
29. He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation. 2012;126:1705-1716.
30. Russo SB, Baicu CF, Van Laer A, Geng T, Kasiganesan H, Zile MR, Cowart LA. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest. 2012;122:3919-3930.
31. Pavoine C, Pecker F. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res. 2009;82:175-183.
32. Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem. 1997;272:16281-16287.
33. Reibel DK, O'Rourke B, Foster KA, Hutchinson H, Uboh CE, Kent RL. Altered phospholipid metabolism in pressure-overload hypertrophied hearts. Am J Physiol. 1986;250:H1-H6.
34. Chien KR, Peau RG, Farber JL. Ischemic myocardial cell injury. Prevention by chlorpromazine of an accelerated phospholipid degradation and associated membrane dysfunction. Am J Pathol. 1979;97:505-529.
35. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev. 2002;7:161-173.
36. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, Teasuro P, Varricchio M, D'Onofrio F. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 1994;43:174-179.
37. Lommi J, Kupari M, Yki-Järvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1998;81:45-50.
38. Kataoka K, Nohara R, Hosokawa R, Hirai T, Okuda K, Li-Guang C, Fujibayashi Y, Fujita M, Konishi J, Sasayama S. Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. J Nucl Med. 2001;42:124-129.
39. Tuunanen H, Engblom E, Naum A, Scheinin M, Någren K, Airaksinen J, Nuutila P, Iozzo P, Ukkonen H, Knuuti J. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail. 2006;12:644-652.
40. Rennison JH, McElfresh TA, Okere IC, Patel HV, Foster AB, Patel KK, Stoll MS, Minkler PE, Fujioka H, Hoit BD, Young ME, Hoppel CL, Chandler MP. Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure. Cardiovasc Res. 2008;79:331-340.
41. Wittels B, Spann JF Jr. Defective lipid metabolism in the failing heart. J Clin Invest. 1968;47:1787-1794.
42. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416-426.
43. Smith SH, Kramer MF, Reis I, Bishop SP, Ingwall JS. Regional changes in creatine kinase and myocyte size in hypertensive and nonhypertensive cardiac hypertrophy. Circ Res. 1990;67:1334-1344.
44. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF, Taegtmeyer H, O'Donnell JM, Lewandowski ED. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009;104:805-812.
45. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation. 2007;115:2033-2041.
46. Leong HS, Grist M, Parsons H, Wambolt RB, Lopaschuk GD, Brownsey R, Allard MF. Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol Endocrinol Metab. 2002;282:E1039-E1045.
47. Gupte SA, Levine RJ, Gupte RS, Young ME, Lionetti V, Labinskyy V, Floyd BC, Ojaimi C, Bellomo M, Wolin MS, Recchia FA. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J Mol Cell Cardiol. 2006;41:340-349.
48. Bachowski GJ, Thomas JP, Girotti AW. Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism. Lipids. 1988;23:580-586.
49. Courtois F, Suc I, Garofalo C, Ledoux M, Seidman E, Levy E. Ironascorbate alters the efficiency of Caco-2 cells to assemble and secrete lipoproteins. Am J Physiol Gastrointest Liver Physiol. 2000;279:G12-G19.
50. Alexander D, Lombardi R, Rodriguez G, Mitchell MM, Marian AJ. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest. 2011;41:527-538.